Clinical efficacy and safety of cilostazol: A critical review of the literature

Drugs

Volumn 75, Issue 4, 2015, Pages 377-395

  Rogers, Kelly C ^a   Oliphant, Carrie S ^b   Finks, Shannon W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b METHODIST UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

AREA UNDER THE CURVE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CRITICAL LIMB ISCHEMIA; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; HUMAN; INTERMITTENT CLAUDICATION; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; RESTENOSIS; REVIEW; SECONDARY PREVENTION; TACHYCARDIA; THERAPY EFFECT; VASCULAR DISEASE; ANIMAL; CHEMICALLY INDUCED; HEMORRHAGE; PERIPHERAL ARTERIAL DISEASE; TREATMENT OUTCOME;

ANIMALS; HEMORRHAGE; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84925534331     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0364-3     Document Type: Review

References (85)

1. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72(4):634-46. doi: 10.1111/j.1365-2125.2011.04034.x.
2. Si Hayashi, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35(1):237-43. doi: 10.1161/01.hyp.35.1.237.
3. Package Insert. Pletal (cilostazol). Rockville: Otsuka America Pharmaceutical, Inc.
4. Pan XAE, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphidesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48:827-35. doi: 10.1016/0006-2952(94)90062-0.
5. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4(Suppl. 2):S14-9.
6. Shin ES, Lee JH, Yoo SY, Park Y, Hong YJ, Kim MH, et al. A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. Heart (British Cardiac Society). 2014;100(19):1531-6. doi: 10.1136/heartjnl-2014-305986.
7. Park SWLC, Kim HS, et al. Comparison of cilostazol versus ticlopidine threapy after stent implantation. Am J Cardiol. 1999;84:511-4. doi: 10.1016/S0002-9149(99)00368-9.
8. Lee SW, Park SW, Hong MK, Lee CW, Kim YH, Park JH, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95(7):859-62. doi: 10.1016/j.amjcard.2004.12.012.
9. Hashiguchi MOK, Nakazawa R, Kishino S, Mochizuki M, Shiga T. Comparison of cilostazol and ticlopodine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther. 2004;18:211-7. doi: 10.1023/B:CARD.0000033642.49162.04.
10. Kubota YKK, Uchida H, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol. 1995;30:532-7.
11. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7):1103-8. doi: 10.1016/j.amjcard.2007.05.032.
12. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100(1):21-6. doi: 10.1161/01.CIR.100.1.21.
13. Park SWLC, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499-503. doi: 10.1016/S0002-9149(00)01001-8.
14. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112(18):2826-32. doi: 10.1161/CIRCULATIONAHA.104.530097.
15. Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000;36(3):351-60.
16. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;2:S14-9. doi: 10.1046/j.1463.2002.0040s2s14.x.
17. Elam MBHJ, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942-7.
18. Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart (British Cardiac Society). 2011;97(8):641-7. doi: 10.1136/hrt.2010.216499.
19. Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J. 2010;159(2):284-291 e1. doi: 10.1016/j.ahj.2009.11.014.
20. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009;119(25):3207-14. doi: 10.1161/CIRCULATIONAHA.108.822791.
21. Anderson JL, Halperin JL, Albert N, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555-70. doi: 10.1016/j.jacc.2013.01.004.
22. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e669S-90S. doi: 10.1378/chest.11-2307.
23. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008;1:CD003748. doi: 10.1002/14651858.CD003748.pub3.
24. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48(1):144-9. doi: 10.1016/j.jvs.2008.02.062.
25. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation. 2013;127(23):2307-15. doi: 10.1161/CIRCULATIONAHA.112.000711.
26. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol. 2008;3(4):1034-40. doi: 10.2215/CJN.05761207.
27. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Tanaka M, et al. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients. Clin Ther. 2010;32(1):24-33. doi: 10.1016/j.clinthera.2010.01.007.
28. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53(1):48-53. doi: 10.1016/j.jacc.2008.09.020.
29. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011;15(40):1-210. doi: 10.3310/hta15400.
30. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;10:CD003748. doi: 10.1002/14651858.CD003748.pub4.
31. Lund-Kordahl I, Olasveengen TM, Lorem T, Samdal M, Wik L, Sunde K. Improving outcome after out-of-hospital cardiac arrest by strengthening weak links of the local chain of survival; quality of advanced life support and post-resuscitation care. Resuscitation. 2010;81(4):422-6. doi: 10.1016/j.resuscitation.2009.12.020.
32. European Medicines Agency recommends restricting use of cilostazol-containing medicines. 2013.
33. Perez P, Esteban C, Sauquillo JC, Yeste M, Manzano L, Mujal A, et al. Cilostazol and outcome in outpatients with peripheral artery disease. Thromb Res. 2014;134(2):331-5. doi: 10.1016/j.thromres.2014.05.040.
34. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008;47(2):330-6. doi: 10.1016/j.jvs.2007.10.009.
35. Adam DJ, Bradbury AW. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007;33(1):1-2. doi: 10.1016/j.ejvs.2006.11.008.
36. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013;61(24):2428-34. doi: 10.1016/j.jacc.2013.03.036.
37. European Stroke O, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-906. doi: 10.1093/eurheartj/ehr211.
38. Warner CJ, Greaves SW, Larson RJ, Stone DH, Powell RJ, Walsh DB, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014;59(6):1607-14. doi: 10.1016/j.jvs.2013.11.096.
39. Iida O, Yokoi H, Soga Y, Inoue N, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by Cilostazol study. STOP-IC. Circulation. 2013;127(23):2307-15.
40. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):e86-92. doi: 10.1016/j.atherosclerosis.2008.10.023.
41. Azarbal A, Clavijo L, Gaglia MA Jr. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. 2014;. doi: 10.1177/1074248414545126.
42. Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2012;44(6):577-81. doi: 10.1016/j.ejvs.2012.09.020.
43. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(3 Suppl):27a-34a. doi: 10.1016/j.amjcard.2008.11.020.
44. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160(3):543-51. doi: 10.1016/j.ahj.2010.06.004.
45. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919-33. doi: 10.1016/j.jacc.2010.04.047.
46. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945-54. doi: 10.1016/j.jacc.2011.06.059.
47. Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv. 2010;3(10):1008-10. doi: 10.1016/j.jcin.2010.08.011.
48. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEJM. 2007;357(20):2001-15. doi: 10.1056/NEJMoa0706482.
49. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEJM. 2009;361(11):1045-57. doi: 10.1056/NEJMoa0904327.
50. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140. doi: 10.1016/j.jacc.2012.11.019.
51. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;. doi: 10.1016/j.jacc.2014.09.017.
52. Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol. 2010;50(4):415-21. doi: 10.1177/0091270009338940.
53. Rogers KC, Faircloth JM, Finks SW. Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother. 2012;46(6):839-50. doi: 10.1345/aph.1Q765.
54. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J. 2008;155(6):1081-9. doi: 10.1016/j.ahj.2007.12.024.
55. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology. 2012;122(3):133-43. doi: 10.1159/000339238.
56. Chen J, Meng H, Xu L, Liu J, Kong D, Chen P, et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis. 2014;. doi: 10.1007/s11239-014-1090-5.
57. Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1):e000068. doi: 10.1136/openhrt-2014-000068.
58. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. doi: 10.1001/jama.2011.290.
59. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEJM. 2012;367(22):2100-9. doi: 10.1056/NEJMoa1209979.
60. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007.
61. Yang TH, Jin HY, Choi KN, Do U, Kim HJ, Chung SR, et al. Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. Int J Cardiol. 2013;168(1):207-11. doi: 10.1016/j.ijcard.2012.09.093.
62. Park KH, Jeong MH, Lee KH, Sim DS, Yoon HJ, Yoon NS, et al. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction. J Cardiol. 2014;63(2):99-105. doi: 10.1016/j.jjcc.2013.07.004.
63. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-57. doi: 10.1001/jama.2009.1232.
64. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-41. doi: 10.1016/j.jacc.2010.05.013.
65. Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). JACC Cardiovasc Interv. 2013;6(9):932-42. doi: 10.1016/j.jcin.2013.04.022.
66. Centers for Disease C, Prevention. Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke-United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(5):113-7.
67. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al. Proportion of different subtypes of stroke in China. Stroke. 2003;34(9):2091-6. doi: 10.1161/01.str.0000087149.42294.8c.
68. Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, et al. Incidence and trends of stroke and its subtypes in China: results from three large cities. Stroke. 2006;37(1):63-8. doi: 10.1161/01.str.0000194955.34820.78.
69. Yang QD, Niu Q, Zhou YH, Liu YH, Xu HW, Gu WP, et al. Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis. 2004;17(4):303-13. doi: 10.1159/000077341.
70. Watanabe K, Nakase H, Kimura Y. Effect of cilostazol on experimental cerebral infarction in rabbits. Arzneimittelforschung. 1986;36(7):1022-4.
71. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke. 1989;20(5):668-73.
72. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9(4):147-57. doi: 10.1053/jscd.2000.7216.
73. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2.
74. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959-68. doi: 10.1016/S1474-4422(10)70198-8.
75. Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol. 2013;112(8):1230-4. doi: 10.1016/j.amjcard.2013.05.067.
76. Qian Y, Bi Q. Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. Eur J Med Res. 2013;18:53. doi: 10.1186/2047-783X-18-53.
77. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947. doi: 10.1161/STR.0b013e318284056a.
78. Fujita K, Komatsu Y, Sato N, Higuchi O, Kujiraoka Y, Kamezaki T, et al. Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. Neurol Med Chir (Tokyo). 2011;51(12):819-24.
79. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, et al. Cilostazol in acute ischemic stroke treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036.
80. Shimizu H, Tominaga T, Ogawa A, Kayama T, Mizoi K, Saito K, et al. Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. J Stroke Cerebrovasc Dis. 2013;22(4):449-56. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.009.
81. Shinohara Y. Japanese guidelines for the management of stroke 2009: important revised points necessary for the neurologist. Rinsho Shinkeigaku. 2010;50(11):808-11.
82. European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083.
83. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-236. doi: 10.1161/str.0000000000000024.
84. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79(4):541-8. doi: 10.1002/ccd.23304.
85. Ikushima I, Yonenaga K, Iwakiri H, Nagoshi H, Kumagai H, Yamashita Y. A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine. Med Devices. 2011;4:83-9. doi: 10.2147/MDER.S21629.